ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

The phase 3 ZEUS trial found that the drug ziltivekimab failed to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and chronic kidney disease. Despite lowering inflammatory biomarkers, the treatment did not provide the expected clinical benefit compared to a placebo.
Why it matters
The failure of this trial highlights the complexities of targeting inflammation to treat heart disease and underscores the necessity of rigorous clinical testing.
Ziltivekimab, an interleukin-6 (IL-6) inhibitor, did not reduce cardiovascular events compared with placebo in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation in the phase 3 ZEUS trial, according to results presented at the American Heart Association (AHA) Scientific Sessions 2026 and published in the New England Journal of Medicine.1
Ziltivekimab, a monoclonal antibody neutralizing the IL-6 ligand, lowered high-sensitivity C-reactive protein (hsCRP) and other inflammatory biomarkers in a phase 2 study of patients with CKD. The ZEUS rationale drew on mendelian randomization data implicating IL-6 signaling in atherosclerosis and on CANTOS, in which interleukin-1β inhibition with canakinumab lowered recurrent cardiovascular event rates.1
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in